Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer

详细信息    查看全文

• 作者：Chan-Young Ock ; Do-Youn Oh ; Joongyub Lee ; Tae-Yong Kim ; Kyung-Hun Lee…
• 关键词：Weight loss ; Chemotherapy ; Survival ; Prognostic factor ; Gastric cancer
• 刊名：Gastric Cancer
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：19
• 期：2
• 页码：597-606
• 全文大小：1,406 KB
• 参考文献：1.Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34:503–9.CrossRef PubMed
  2.Lu Z, Yang L, Yu J, Lu M, Zhang X, Li J, et al. Change of body weight and macrophage inhibitory cytokine-1 during chemotherapy in advanced gastric cancer: what is their clinical significance? PLoS One. 2014;9:e88553.CrossRef PubMed PubMedCentral
  3.Sanchez-Lara K, Ugalde-Morales E, Motola-Kuba D, Green D. Gastrointestinal symptoms and weight loss in cancer patients receiving chemotherapy. Br J Nutr. 2013;109:894–7.CrossRef PubMed
  4.Innominato PF, Giacchetti S, Moreau T, Bjarnason GA, Smaaland R, Focan C, et al. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Cancer. 2013;119:2564–73.CrossRef PubMed
  5.Choi Y, Kim TY, Lee KH, Han SW, Oh DY, Im SA, et al. The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy. J Pain Symptom Manage. 2014;48:13–25.CrossRef PubMed
  6.Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer. 2004;90:1905–11.CrossRef PubMed PubMedCentral
  7.Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69:491–7.CrossRef PubMed
  8.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRef PubMed
  9.Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro–oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRef PubMed
  10.Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010:CD004064.
  11.Oba K, Paoletti X, Bang YJ, Bleiberg H, Burzykowski T, Fuse N, et al. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer. 2013;49:1565–77.CrossRef PubMed
  12.DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–45.CrossRef PubMed
  13.Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.CrossRef PubMed
  14.Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.CrossRef PubMed
  15.Knuiman MW, Divitini ML, Buzas JS, Fitzgerald PE. Adjustment for regression dilution in epidemiological regression analyses. Ann Epidemiol. 1998;8:56–63.CrossRef PubMed
  16.Davidson C, Smith D, Morgan DB. Diurnal pattern of water and electrolyte excretion and body weight in idiopathic orthostatic hypotension. The effect of three treatments. Am J Med. 1976;61:709–15.CrossRef PubMed
  17.Vieweg WV, Godleski LS, Graham P, Barber J, Goldman F, Kellogg E, et al. Abnormal diurnal weight gain among institutionalized patients with manic-depressive spectrum disorders. Psychiatr Med. 1990;8:129–34.PubMed
  18.Vieweg WV, Godleski LS, Graham P, Barber J, Goldman F, Kellogg E, et al. Abnormal diurnal weight gain among long-term patients with schizophrenic disorders. Schizophr Res. 1988;1:67–71.CrossRef PubMed
  19.Baldwin C, Spiro A, Ahern R, Emery PW. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2012;104:371–85.CrossRef PubMed
  20.Elia M, Bokhorst-de Van, van der Schueren MA, Garvey J, Goedhart A, Lundholm K, Nitenberg G, et al. Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. Int J Oncol. 2006;28:5–23.PubMed
  21.Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut. 2005;54:540–5.CrossRef PubMed PubMedCentral
  22.Oldervoll LM, Loge JH, Lydersen S, Paltiel H, Asp MB, Nygaard UV, et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist. 2011;16:1649–57.CrossRef PubMed PubMedCentral
  23.Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30:3271–6.CrossRef PubMed PubMedCentral
  24.Gonzalez MC, Pastore CA, Orlandi SP, Heymsfield SB. Obesity paradox in cancer: new insights provided by body composition. Am J Clin Nutr. 2014;99:999–1005.CrossRef PubMed
  25.Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010;21:1594–8.CrossRef PubMed
  26.Pezaro C, Mukherji D, Tunariu N, Cassidy AM, Omlin A, Bianchini D, et al. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. Br J Cancer. 2013;109:325–31.CrossRef PubMed PubMedCentral
  27.Kir S, White JP, Kleiner S, Kazak L, Cohen P, Baracos VE, et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature. 2014;513:100–4.CrossRef PubMed PubMedCentral
  
• 作者单位：Chan-Young Ock (1)
  Do-Youn Oh (1) (2)
  Joongyub Lee (3)
  Tae-Yong Kim (1) (2)
  Kyung-Hun Lee (1) (2)
  Sae-Won Han (1) (2)
  Seock-Ah Im (1) (2)
  Tae-You Kim (1) (2)
  Yung-Jue Bang (1) (2)
  
  1. Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea
  2. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
  3. Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Korea
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Gastroenterology
  Surgical Oncology
  Pathology
  Radiotherapy
  
• 出版者：Springer Japan
• ISSN：1436-3305

文摘

Background Weight loss during chemotherapy is a significant prognostic factor for poor survival in patients with advanced gastric cancer (AGC). However, in most studies, weight loss was measured at the end of chemotherapy, limiting its clinical use. In this study, we evaluated whether weight loss during the first month of chemotherapy could predict survival outcomes in patients with AGC.